Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy

Share this content:
Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.
Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.

Patients with ovarian cancer responsive to platinum-based chemotherapy may experience a prolongation of progression-free survival (PFS) with rucaparib maintenance therapy, according to a study published in The Lancet. 1

Rucaparib is a poly(ADP-ribose) polymerase inhibitor that demonstrated anticancer activity in ovarian cancer with BRCA mutation or high percentage of genome-wide loss of heterozygosity. For the phase 3 ARIEL3 trial (ClinicalTrials.gov Identifier: NCT01968213), investigators evaluated the effect of rucaparib vs placebo among patients who had responded to second-line or later platinum-based chemotherapy.

Researchers randomly assigned 564 patients to receive oral rucaparib 600 mg twice daily or placebo. Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen. Patients were also stratified into 3 cohorts based on genetic mutations.

Median PFS among patients with ovarian cancer characterized by BRCA-mutations was 16.6 months (95% CI, 13.4-22.9) in the rucaparib arm vs 5.4 months (95% CI, 3.4-6.7) among patients in the placebo arm (hazard ratio [HR], 0.23; 95% CI, 0.16-0.34; P < .0001).

Patients with homologous recombination deficient carcinoma treated with rucaparib had a PFS of 13.6 months (95% CI, 10.9-16.2) vs 5.4 months (95% CI, 5.1-5.6) in patients receiving placebo (HR, 0.32; 95% CI, 0.24-0.42; P < .0001).

Among patients without gene mutations in the intent-to-treat cohort, PFS in the rucaparib arm was 10.8 months (95% CI, 8.3-11.4) vs 5.4 months (95% CI, 5.3-5.5) in the placebo arm (HR, 0.36; 95% CI, 0.30-0.45; P < .0001).

Grade 3 or greater treatment-emergent adverse events (AE) were reported in 56% of patients receiving rucaparib and 15% in patients receiving placebo.

The authors conclude that “ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy.”

Reference

  1. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Sep 12. doi: 10.1016/S0140-6736(17)32440-6 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters